A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene Therapy
Overview
- Phase
- Phase 4
- Intervention
- Risdiplam
- Conditions
- Muscular Atrophy, Spinal
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 28
- Locations
- 27
- Primary Endpoint
- Change from Baseline in the Raw Score of Bayley Scales of Infant and Toddler Development - Third Edition (BSID-III) Gross Motor Score at 72 Weeks of Risdiplam Treatment
- Status
- Recruiting
- Last Updated
- last month
Overview
Brief Summary
This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy (SMA) and 2 SMN2 copies who have previously received onasemnogene abeparvovec. Participants are children < 2 years of age genetically diagnosed with SMA.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\<2 years of age at the time of informed consent
- •Confirmed diagnosis of 5q-autosomal recessive SMA, including genetic confirmation of homozygous deletion or compound heterozygosity predictive of loss of function of the Survival of Motor Neuron 1 (SMN1) gene
- •Confirmed presence of two SMN2 gene copies as documented through laboratory testing
- •Administration of onasemnogene abeparvovec pre-symptomatically or post-symptomatically
- •Has received onasemnogene abeparvovec for SMA no less than 13 weeks, but not more than months 30 weeks, prior to enrollment
- •If treated with risdiplam prior to onasemnogene abeparvovec, risdiplam treatment must not have exceeded 3 weeks and must be discontinued 1 day prior to onasemnogene abeparvovec administration
- •Has, in the opinion of the investigator, not experienced clinically significant decline in function from the time of onasemnogene abeparvovec administration
Exclusion Criteria
- •Previous or current enrolment in investigational study prior to initiation of study treatment
- •Any unresolved standard-of-care laboratory abnormalities per the onasemnogene abeparvovec prescribing information
- •Concomitant or previous administration of an SMN2-targeting antisense oligonucleotide
- •Concomitant or previous use of an anti-myostatin agent
- •Participants requiring invasive ventilation or tracheostomy
- •Participants requiring awake non-invasive ventilation or with awake hypoxemia (Arterial Oxygen Saturation \[SaO2\] \<95%) with or without ventilator support
- •Presence of feeding tube and an OrSAT score of 0
- •Hospitalization for pulmonary event within the last 2 months, or any planned hospitalization at the time of screening
- •Any major illness requiring hospitalization within 1 month before the screening examination or any febrile illness within 1 week prior to screening and up to first dose administration.
Arms & Interventions
Risdiplam
Participants will receive risdiplam orally once daily for 72 weeks (Treatment Period). The Treatment Period will be followed by a 1-year Treatment Extension Period for a total study duration of 120 weeks (approximately 2.5 years) for each participant enrolled.
Intervention: Risdiplam
Outcomes
Primary Outcomes
Change from Baseline in the Raw Score of Bayley Scales of Infant and Toddler Development - Third Edition (BSID-III) Gross Motor Score at 72 Weeks of Risdiplam Treatment
Time Frame: Baseline, Week 72
The BSID-III is a standardized assessment commonly used to evaluate developmental functioning of infants and young children between 1 month and 42 months of age. The gross motor scale measures the movement of the limbs and torso. Items assess static positioning (e.g., sitting, standing); dynamic movement, including locomotion and coordination; balance; and motor planning. The gross motor scale consists of 72 items scored at 0 (unable to perform) or 1 (criteria for item achieved). A higher raw score indicates improvement.
Secondary Outcomes
- Percentage of Participants With Serious Adverse Events(Up to 120 weeks)
- Percentage of Participants With Adverse Events(Up to 120 weeks)
- Percentage of Participants With Treatment Discontinuation Due to Adverse Events(Up to 120 weeks)